{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:31:07Z","timestamp":1790965867944,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Human epidermal growth receptor 2 (HER2) targeted therapies have survival benefit in adjuvant and metastatic HER2 positive breast cancer but are associated with cardiac dysfunction. Current U.S. Food and Drug Administration recommendations limit the use of HER2 targeted agents to patients with normal left ventricular (LV) systolic function.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The objective of the SAFE-HEaRt study is to evaluate the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and mildly reduced left ventricular ejection fraction (LVEF) with optimized cardiac therapy. Thirty patients with histologically confirmed HER2 positive breast cancer (stage I\u2013IV) and reduced LVEF (40% to 49%) who plan to receive HER2 targeted therapy for \u22653 months will be enrolled. Prior to initiation on study, optimization of heart function with beta-blockers and angiotensin converting enzyme inhibitors will be initiated. Patients will be followed by serial echocardiograms and cardiac visits during and 6 months after completion of HER2 targeted therapy. Myocardial strain and blood biomarkers, including cardiac troponin I and high-sensitivity cardiac troponin T, will be examined at baseline and during the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>LV dysfunction in patients with breast cancer poses cardiac and oncological challenges and limits the use of HER2 targeted therapies and its oncological benefits. Strategies to prevent cardiac dysfunction associated with HER2 targeted therapy have been limited to patients with normal LVEF, thus excluding patients who may receive the highest benefit from those strategies. SAFE-HEaRt is the first prospective pilot study of HER2 targeted therapies in patients with reduced LV function while on optimized cardiac treatment that can provide the basis for clinical practice changes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0412","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T02:58:25Z","timestamp":1489805905000},"page":"518-525","source":"Crossref","is-referenced-by-count":33,"title":["SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function"],"prefix":"10.1093","volume":"22","author":[{"given":"Filipa","family":"Lynce","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, D.C., USA"},{"name":"MedStar Washington Hospital Center, Washington, D.C., USA"},{"name":"MedStar Heart and Vascular Institute, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming T.","family":"Tan","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico M.","family":"Asch","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center, Washington, D.C., USA"},{"name":"MedStar Heart and Vascular Institute, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center, Sibley Memorial Hospital, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Dang","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New, York New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Swain","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, D.C., USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"2021122507535377200_onco12094-bib-0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"2021122507535377200_onco12094-bib-0002","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","article-title":"Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group","volume":"11","author":"Seshadri","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0003","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122507535377200_onco12094-bib-0004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122507535377200_onco12094-bib-0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122507535377200_onco12094-bib-0006","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122507535377200_onco12094-bib-0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/sonc.2001.26436","article-title":"Liposomal anthracyclines for breast cancer","volume":"28","author":"Sparano","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122507535377200_onco12094-bib-0009","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","article-title":"Clinical cardiac tolerability of trastuzumab","volume":"22","author":"Perez","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0011","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0012","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0013","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0014","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2021122507535377200_onco12094-bib-0015","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2021122507535377200_onco12094-bib-0016","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122507535377200_onco12094-bib-0017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-014-2836-7","article-title":"Risk of cardiovascular adverse events from trastuzumab (Herceptin(\u00ae)) in elderly persons with breast cancer: A population-based study","volume":"144","author":"Tsai","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507535377200_onco12094-bib-0018","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0019","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2015.09.012","article-title":"Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival","volume":"52","author":"Rossi","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122507535377200_onco12094-bib-0021","volume-title":"Herceptin [package insert]","year":"2015"},{"key":"2021122507535377200_onco12094-bib-0022","volume-title":"Kadcyla [package insert]","year":"2016"},{"key":"2021122507535377200_onco12094-bib-0023","volume-title":"Perjeta [package insert]","year":"2016"},{"key":"2021122507535377200_onco12094-bib-0024","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/1471-2407-11-318","article-title":"Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101\u2013Breast): A randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI","volume":"11","author":"Pituskin","year":"2011","journal-title":"BMC Cancer"},{"key":"2021122507535377200_onco12094-bib-0025","author":"Pituskin","year":"2015"},{"key":"2021122507535377200_onco12094-bib-0026","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2021122507535377200_onco12094-bib-0027","first-page":"1030","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer:","volume":"2","author":"Boekhout","year":"2016","journal-title":"A randomized clinical trial. JAMA Oncol"},{"key":"2021122507535377200_onco12094-bib-0028","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacc.2005.11.063","article-title":"Measurement of strain and strain rate by echocardiography: Ready for prime time?","volume":"47","author":"Marwick","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2021122507535377200_onco12094-bib-0029","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2021122507535377200_onco12094-bib-0030","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"2021122507535377200_onco12094-bib-0031","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021122507535377200_onco12094-bib-0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2021122507535377200_onco12094-bib-0033","first-page":"755","article-title":"Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: Endorsed by","volume":"22","author":"Douglas","year":"2009","journal-title":"the American College of Cardiology Foundation. J Am Soc Echocardiogr"},{"key":"2021122507535377200_onco12094-bib-0034","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122507535377200_onco12094-bib-0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomized controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"2021122507535377200_onco12094-bib-0036","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/(SICI)1097-0258(19961015)15:19<2037::AID-SIM339>3.0.CO;2-Z","article-title":"Continuous and group sequential conditional probability ratio tests for Phase II clinical trials","volume":"15","author":"Tan","year":"1996","journal-title":"Stat Med"},{"key":"2021122507535377200_onco12094-bib-0037","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/pst.478","article-title":"A flexible multi-stage design for phase II oncology trials","volume":"10","author":"Tan","year":"2011","journal-title":"Pharm Stat"},{"key":"2021122507535377200_onco12094-bib-0038","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2021122507535377200_onco12094-bib-0039","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/518\/41916118\/oncolo_22_5_518.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/5\/518\/41916118\/oncolo_22_5_518.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:55:14Z","timestamp":1640418914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/5\/518\/6439020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,3,17]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0412","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,1]]},"published":{"date-parts":[[2017,3,17]]}}}